Navigation Links
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
Date:1/9/2009

ROCKVILLE, Md., Jan. 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the 27th Annual JPMorgan Healthcare Conference will be webcast and may be accessed at www.hgsi.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

A member of Human Genome Sciences' senior management team will present an overview of the company on Wednesday, January 14, 2009 at 7:30 am Pacific Time (10:30 am Eastern Time).

Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several weeks after the live event.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at www.hgsi.com.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
2. HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services
3. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
4. Video: 8-Minute Film Documentary Explores Why Humans Age
5. Scopus to Expand Arts & Humanities Coverage
6. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
7. Mexican Department of Public Health to Launch Screening for Human Papillomavirus (HPV), Cause of Cervical Cancer
8. Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
9. Human Pheromone Sciences Announces Third Quarter Results
10. Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
11. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... ... August 09, 2017 , ... SPIE, the ... laboratories — the Wellman Center for Photomedicine, the Manstein Lab in the Cutaneous ... Beckman Laser Institute at University of California, Irvine — and the Hillenkamp family ...
(Date:8/10/2017)... (PRWEB) , ... August 10, 2017 , ... ... the stock market news outlet had initiated coverage on Next Group Holdings, Inc. ... and underserved consumer markets geared toward those that cannot engage in traditional banking ...
(Date:8/8/2017)... ... August 08, 2017 , ... HumanZyme ... in human cells, today announced the launch of HumanKine® Interferon beta ... I family of interferons that activate Th1-type innate immune responses against viral and bacterial ...
(Date:8/8/2017)... ... 08, 2017 , ... Myoderm , a global clinical trial drug supply ... announcement comes on the heels of the opening of Myoderm’s European warehouse facility earlier ... to adding staff and establishing operations to support its customers around the world. ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):